A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7077-7084

  Munster, Pamela N ^a,e   Rubin, Eric H ^b,d   Van Belle, Simon ^c   Friedman, Evan ^d   Patterson, Jaclyn K ^d   Van Dyck, Kristien ^d   Li, Xiadong ^d   Comisar, Wendy ^d   Chodakewitz, Jeffery A ^d   Wagner, John A ^d   Iwamoto, Marian ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c GHENT UNIVERSITY   (Belgium)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PLACEBO; VORINOSTAT;

ADULT; ADVANCED CANCER; AGED; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEART RATE; HEMATOLOGIC MALIGNANCY; HOLTER MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG CANCER; LYMPHOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; NAUSEA; OVARY CANCER; PANCREAS CANCER; PERITONEUM PSEUDOMYXOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOFT TISSUE SARCOMA; SOLID TUMOR; THYROID CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERUS CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS; RISK; TREATMENT OUTCOME;

EID: 72549108593     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1214     Document Type: Article

References (21)

1. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202. (Pubitemid 33741894)
2. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-1356
3. Zolinza [package insert]. Whitehouse Station (NJ): Merck & Co.; 2006.
4. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-3773
5. Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res 2006;12:3871-3874
6. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-1802
7. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 2008;26:332-333
8. Fischer T, Patnaik A, Bhalla K, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. JC lin Oncol 2005;23:218S.
9. Rowinsky EK, de Bono J, Deangelo DJ, et al. Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol 2005;23:224S.
10. U.S. Department of Health and Human Services, Food and Drug Administration, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available from: http://www.fda.gov/cder/Guidance/6922fnl.htm; 2005 October. Accessed 2009 May 11.
11. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-1066
12. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931
13. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-3588
14. Rubin EH, Agrawal NGB, Friedman EJ, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006;12:7039-7045
15. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. JClin Pharmacol 2008;48:726-733
16. Du LH, Musson DG, Wang AQ. High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. Rapid Commun Mass Spectrom 2005;19:1779-1787
17. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008;84:475-480
18. Peeters M, Janssen K, Kakuda TN, et al. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother 2008;42:757-765
19. Malik M, Andreas JO, Hnatkova K, et al. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 2008;84:595-603.
20. Rosillon D, Astruc B, Hulhoven R, et al. Effect of brivaracetam on cardiac repolarisation - a thorough QT study. Curr Med Res Opin 2008;24:2327-2337
21. Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br JCli n Pharmacol 2008;66:396-404.